Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) announced management will participate in two investor fireside chats in November 2025. Guggenheim’s 2nd Annual Healthcare Innovation Conference is scheduled for Monday, November 10, 2025 at 11:00–11:25 a.m. ET. Jefferies 2025 Global Healthcare Conference is scheduled for Wednesday, November 19, 2025 at 11:30–11:55 a.m. ET (4:30–4:55 p.m. GMT).
The sessions will be webcast live and accessible via Relay Therapeutics’ investor Events page at https://ir.relaytx.com/news-events/events-presentations. An archived replay will be available for up to 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – RLAY
On the day this news was published, RLAY declined 1.15%, reflecting a mild negative market reaction. Argus tracked a trough of -12.6% from its starting point during tracking. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $1.23B at that time.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November:
- Guggenheim’s 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m. ET
- Jefferies 2025 Global Healthcare Conference on Wednesday, November 19, 2025 at 11:30-11:55 a.m. ET (4:30-4:55 p.m. GMT)
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) present at Guggenheim’s 2nd Annual Healthcare Innovation Conference?
When is Relay Therapeutics (RLAY) scheduled to speak at the Jefferies 2025 Global Healthcare Conference?
How can investors watch the Relay Therapeutics (RLAY) fireside chats live?
Will Relay Therapeutics (RLAY) make replays of the investor presentations available?
What topics will Relay Therapeutics (RLAY) management cover in the November 2025 fireside chats?
Where can I find the exact webcast links and event times for Relay Therapeutics (RLAY)?
